null
Mezigdomide Triplet Cuts Progression Risk by 52% in Relapsed MyelomaByAndrea Eleazar, MHSMay 30th 2026
Elrexfio Improves Progression-Free Survival in Multiple Myeloma Phase 3 TrialByQuincy AttobrahApril 30th 2026